Bionure, a leader in the development of RNA therapies for diseases of the Central Nervous System, has entered a strategic collaboration with the Hospital del Mar Research Institute, a leader in neuroscience. This alliance promises to transform the treatment landscape for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Epilepsy, among others.
RNA Therapies: A Ray of Hope for Patients
Bionure's innovative RNA technology, combined with the clinical expertise of Hospital del Mar, opens up new possibilities for patients with neurodegenerative diseases that have a genetic component. These advanced therapies not only seek to slow the progression of the disease, but also offer the possibility of repairing neuronal damage, something unheard of until now.
Hospital del Mar: Pioneer in Neurological Research
The Hospital del Mar Research Institute, located at the Parc de Recerca Biomèdica de Barcelona (PRBB), is renowned for its Neurosciences Programme, which includes 20 clinical research groups and 700 professionals, provides cutting-edge infrastructure and a multidisciplinary team specializing in neurodegenerative diseases.
Statement: ‘This collaboration marks a before and after in the treatment of neurodegenerative diseases,’ says Carmen Sanfrancisco, CEO of Bionure. ‘RNA therapies represent the future of personalized medicine for these complex conditions. Dr. Pablo Villoslada, director of the Neuroscience Research Programme at the Hospital del Mar Research Institute, adds: ‘Our expertise in neuroscience, combined with Bionure's RNA technology, positions us at the forefront of translational research in diseases of the central nervous system’.
About Bionure
Bionure is a pioneer in the development of RNA therapeutics for neurodegenerative diseases, with a proven track record in the development of neuroprotective compounds such as BN201 currently licensed to Oculis and in phase II for optic neuritis.
About the Hospital del Mar Research Institute
The Hospital del Mar Research Institute is a leading centre in biomedical research, excelling in neurosciences and in the development of innovative therapies for diseases of the central nervous system.
For further information:
For Bionure: comunicacion@bionure.com
For HMRI: comunicacio@hospitaldelmar.cat
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...
